As downregulation of SIRT-3 was found to be having a retrograde effect on p53 mediated mitochondrial and neuronal damage in AD, its modulation by therapeutics was found to ameliorate mitochondrial pathology and neurodegeneration in AD (Lee et al., 2018). This evidence concerns the gene TP53 and Alzheimer disease.